The following is a summary of “Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection ...

but I-PRESERVE excluded patients who had a prior documented ejection fraction <40%, which minimized the confounder that patients with systolic heart failure whose ejection fraction might have ...

The FDA has granted approval for the ANDA of Lupin’s Sacubitril and Valsartan Tablets for heart failure patients.

AI model transforms heart failure care by precisely identifying cases and enhancing quality evaluations in clinical practice.

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

However, human trials to date are limited to small physiologic studies of patients with heart failure and reduced ejection fraction (most ... of sildenafil seen in 'systolic' heart failure to ...

Lupin receives US FDA approval for sacubitril and valsartan tablets: Our Bureau, Mumbai Friday, January 24, 2025, 15:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) announc ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

Cantor Fitzgerald issued their FY2025 earnings estimates for shares of CVRx in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post ...